DRG 915 Overview

DRG 915 covers inpatient encounters for allergic reactions where a Major Complication or Comorbidity is present, typically including severe systemic responses requiring intensive monitoring or organ support. This Diagnosis-Related Group captures higher resource use driven by severity, extended length of stay, and intervention intensity. It is important for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative payment weight compared with lower-severity groupings. Correct clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus influence reimbursement.

Across commercial payers the observed rate range spans from about $370 (BCBS minimum) up to $59K (Anthem maximum), with mean payer averages clustering between roughly $15K and $28K. The widest spread is between BCBS’s minimum reported value and Anthem’s maximum (~$59K), reflecting considerable variability across payers. See the table and chart below for payer-level percentiles and distributions.

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments as published in the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($17.6k), average submitted covered charges ($76.8k), average Medicare payment amount ($14.2k), and total discharges (1.8k).

• Acute emergency intervention trials evaluating rapid treatments for severe, life-threatening allergic reactions (anaphylaxis, angioedema) in hospitalized patients: these studies focus on protocols for immediate airway management, dosing and timing of emergency medications, and escalation-of-care algorithms in the ED and inpatient setting. The patient population includes adults and children admitted with an acute allergic reaction accompanied by major complication(s) (e.g., respiratory failure, shock) requiring critical care interventions. Results inform hospital protocols, resource utilization, and short-term outcomes that are directly relevant to providers managing high-acuity cases and payers concerned with cost, length of stay, and avoidance of intensive care utilization.
• Comparative effectiveness trials of inpatient management strategies for complex allergic reactions with major complications: these trials compare treatment pathways (for example, different corticosteroid regimens, adjunctive immunomodulatory approaches, or observation versus early escalation to intensive monitoring) in patients who have survived the initial emergency phase but remain at high risk for progression or biphasic reactions. The studied population consists of hospitalized patients with severe allergic reactions and comorbidities that complicate management (e.g., chronic respiratory disease, cardiovascular disease, or immunosuppression). Evidence from these studies guides clinicians on best practices to reduce readmissions, minimize complications, and optimize inpatient resource use, which matters to payers tracking post-discharge outcomes and cost-effectiveness.
• Post-discharge outcomes and health services research examining long-term sequelae, recurrence risk, and systems-level care pathways after a hospitalization for an allergic reaction with major complication: these observational cohort studies and pragmatic trials assess rates of recurrence, adherence to follow-up allergy/immunology care, effectiveness of discharge planning (education, prescriptions like epinephrine autoinjectors, outpatient referrals), and the impact of care coordination on downstream utilization. The population includes survivors of severe inpatient allergic reactions across age groups, with attention to social determinants of health and access to outpatient specialty care. Findings are critical for designing care transitions that lower readmission and ED revisit rates, inform coverage decisions for preventive interventions, and help payers and health systems allocate post-acute resources effectively.